Septerna (NASDAQ:SEPN) Posts Quarterly Earnings Results, Misses Expectations By $0.15 EPS

Key Points

• Septerna reported a quarterly loss of $0.57 per share, missing analyst expectations of a $0.42 loss by $0.15; revenue of $18.88 million also came in below the $20.78 million consensus.
• Despite the earnings miss, shares rose 3.9% to $50.74 in Monday midday trading.
• Analysts’ consensus rating was Moderate Buy, with an average price target of $55.22; insiders sold 32,333 shares worth about $1.38 million over the past 90 days.

Septerna (NASDAQ:SEPN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.15), FiscalAI reports. The business had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%.

Septerna Stock Up 3.9%

Septerna stock traded up $1.89 during midday trading on Monday, reaching $50.74. The stock had a trading volume of 713,677 shares, compared to its average volume of 365,581. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -93.96 and a beta of 2.20. Septerna has a 52-week low of $17.98 and a 52-week high of $51.10. The company has a fifty day moving average of $39.52 and a 200 day moving average of $32.59.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on SEPN shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Septerna in a research note on Thursday, October 15th. HC Wainwright raised their price objective on Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Wells Fargo & Company lifted their target price on Septerna from $50.00 to $61.00 and gave the stock an "overweight" rating in a report on Wednesday, November 4th. Guggenheim boosted their target price on Septerna from $51.00 to $65.00 and gave the company a "buy" rating in a research report on Friday. Finally, JonesTrading boosted their target price on Septerna from $43.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Septerna has a consensus rating of "Moderate Buy" and an average price target of $55.22.

Insider Buying and Selling

In related news, SVP Daniel D. Long sold 3,333 shares of the firm's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company's stock, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Elizabeth Bhatt sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares of the company's stock, valued at $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 32,333 shares of company stock worth $1,375,727. Insiders own 5.80% of the company's stock.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.

Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.